Market Cap 17.44B
Revenue (ttm) 4.24B
Net Income (ttm) 32.61M
EPS (ttm) N/A
PE Ratio 21.91
Forward PE 17.14
Profit Margin 0.77%
Debt to Equity Ratio 0.00
Volume 2,236,700
Avg Vol 1,746,370
Day's Range N/A - N/A
Shares Out 195.28M
Stochastic %K 83%
Beta 0.73
Analysts Sell
Price Target $86.38

Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a select...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 498 6700
Address:
1801 Augustine Cut-Off, Wilmington, United States
JFDI
JFDI Oct. 24 at 7:53 PM
$INCY B/O
0 · Reply
JFais
JFais Oct. 24 at 5:49 PM
$SNDX- Compare $1B+ peak sales potential for Revuforj in r/r AML alone to current $800M EV Not to event mention $INCY/Niktimvo contribution I could be off, but how I see it
0 · Reply
2_logs_higher
2_logs_higher Oct. 24 at 5:40 PM
$AGEN & $INCY, $LLY INCY needs to buy needs to buy Agen LLY needs to buy INCY New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) https://finance.yahoo.com/news/lillys-baricitinib-delivered-near-complete-104500483.html?guccounter=1
1 · Reply
2_logs_higher
2_logs_higher Oct. 24 at 5:35 PM
$AGEN & $INCY INCY needs to buy Agenus! New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) https://finance.yahoo.com/news/lillys-baricitinib-delivered-near-complete-104500483.html?guccounter=1
0 · Reply
JFais
JFais Oct. 24 at 5:10 PM
$SNDX- no need to revisit PTs as of yet, still more to prove (clock ticking for $INCY though if doesn't want to overpay for full Niktimvo rights)
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 3:29 PM
$INCY set for an earnings beat? With a +3.48% Earnings ESP and a Zacks Rank #3, $INCY is poised to surpass expectations for its Q3 2025 earnings. Jakafi's strong sales and promising royalty revenues could fuel this momentum. Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2776437/incyte-gears-up-to-report-q3-earnings-is-a-beat-in-the-cards?cid=sm-stocktwits-2-2776437-body-17533&ADID=SYND_STOCKTWITS_TWEET_2_2776437_BODY_17533
0 · Reply
Doozio
Doozio Oct. 24 at 2:45 PM
The $INCY wincy makes it up da water spout on FRYdays during 🐒🍌🧠⏰♾️
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 2:29 PM
$INCY gearing up for a potential earnings surprise? Jakafi, Opzelura, and the new Niktimvo launch are expected to fuel solid Q3 revenue growth — setting the stage for a possible beat. Full earnings preview here 👉 https://www.zacks.com/stock/news/2776437/incyte-gears-up-to-report-q3-earnings-is-a-beat-in-the-cards?cid=sm-stocktwits-2-2776437-teaser-17512&ADID=SYND_STOCKTWITS_TWEET_2_2776437_TEASER_17512
0 · Reply
StockConsultant
StockConsultant Oct. 24 at 12:15 PM
$INCY Incyte stock, good close and top of range breakout
0 · Reply
pilobious
pilobious Oct. 24 at 12:11 PM
$INCY pre market buying. Very unusual for this stock. I’ve seen the market ignore FDA approval for INCY pre market. Earnings will be strong Tuesday morning.
0 · Reply
Latest News on INCY
Incyte: Strong Growth, Margin Expansion, And Low Valuation

Oct 21, 2025, 11:13 PM EDT - 3 days ago

Incyte: Strong Growth, Margin Expansion, And Low Valuation


3 Biotech Stocks I Am Accumulating

Oct 15, 2025, 2:30 PM EDT - 9 days ago

3 Biotech Stocks I Am Accumulating

ADMA HRMY SNDX XBI


Incyte to Report Third Quarter Financial Results

Oct 8, 2025, 8:00 AM EDT - 17 days ago

Incyte to Report Third Quarter Financial Results


3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 5 weeks ago

3 Potential Biotech Acquisition Targets

AZN ETNB MLYS SNDX TVTX


Incyte to Present at Upcoming Investor Conferences

Aug 19, 2025, 8:00 AM EDT - 2 months ago

Incyte to Present at Upcoming Investor Conferences


Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 1:33 PM EDT - 3 months ago

Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript


Incyte to Report Second Quarter Financial Results

Jul 10, 2025, 8:00 AM EDT - 3 months ago

Incyte to Report Second Quarter Financial Results


Incyte: New CEO Brings A New Possible Outcome

Jul 3, 2025, 6:11 AM EDT - 4 months ago

Incyte: New CEO Brings A New Possible Outcome


Incyte Says FDA Extended Review Period for Opzelura

Jun 20, 2025, 5:10 PM EDT - 4 months ago

Incyte Says FDA Extended Review Period for Opzelura


Incyte Lymphoma Treatment Gets FDA Approval

Jun 18, 2025, 4:12 PM EDT - 4 months ago

Incyte Lymphoma Treatment Gets FDA Approval


Incyte to Present at Upcoming Investor Conference

May 27, 2025, 8:00 AM EDT - 5 months ago

Incyte to Present at Upcoming Investor Conference


JFDI
JFDI Oct. 24 at 7:53 PM
$INCY B/O
0 · Reply
JFais
JFais Oct. 24 at 5:49 PM
$SNDX- Compare $1B+ peak sales potential for Revuforj in r/r AML alone to current $800M EV Not to event mention $INCY/Niktimvo contribution I could be off, but how I see it
0 · Reply
2_logs_higher
2_logs_higher Oct. 24 at 5:40 PM
$AGEN & $INCY, $LLY INCY needs to buy needs to buy Agen LLY needs to buy INCY New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) https://finance.yahoo.com/news/lillys-baricitinib-delivered-near-complete-104500483.html?guccounter=1
1 · Reply
2_logs_higher
2_logs_higher Oct. 24 at 5:35 PM
$AGEN & $INCY INCY needs to buy Agenus! New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) https://finance.yahoo.com/news/lillys-baricitinib-delivered-near-complete-104500483.html?guccounter=1
0 · Reply
JFais
JFais Oct. 24 at 5:10 PM
$SNDX- no need to revisit PTs as of yet, still more to prove (clock ticking for $INCY though if doesn't want to overpay for full Niktimvo rights)
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 3:29 PM
$INCY set for an earnings beat? With a +3.48% Earnings ESP and a Zacks Rank #3, $INCY is poised to surpass expectations for its Q3 2025 earnings. Jakafi's strong sales and promising royalty revenues could fuel this momentum. Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2776437/incyte-gears-up-to-report-q3-earnings-is-a-beat-in-the-cards?cid=sm-stocktwits-2-2776437-body-17533&ADID=SYND_STOCKTWITS_TWEET_2_2776437_BODY_17533
0 · Reply
Doozio
Doozio Oct. 24 at 2:45 PM
The $INCY wincy makes it up da water spout on FRYdays during 🐒🍌🧠⏰♾️
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 2:29 PM
$INCY gearing up for a potential earnings surprise? Jakafi, Opzelura, and the new Niktimvo launch are expected to fuel solid Q3 revenue growth — setting the stage for a possible beat. Full earnings preview here 👉 https://www.zacks.com/stock/news/2776437/incyte-gears-up-to-report-q3-earnings-is-a-beat-in-the-cards?cid=sm-stocktwits-2-2776437-teaser-17512&ADID=SYND_STOCKTWITS_TWEET_2_2776437_TEASER_17512
0 · Reply
StockConsultant
StockConsultant Oct. 24 at 12:15 PM
$INCY Incyte stock, good close and top of range breakout
0 · Reply
pilobious
pilobious Oct. 24 at 12:11 PM
$INCY pre market buying. Very unusual for this stock. I’ve seen the market ignore FDA approval for INCY pre market. Earnings will be strong Tuesday morning.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 24 at 11:08 AM
WATCHLIST OCT 24 2025 $NVDA Schneider Electric Reaffirms Commitment To Supporting 800 VDC Infrastructure For Next-Gen High-Density Rack Architectures $GNTA Genenta Science Teams With Anemocyte To Enhance Off-The-Shelf Lentiviral Vector Plasmid DNA Platform Providing Reliable Materials From Preclinical To Commercial Applications $SEED Origin Agritech Receives New Crop Seed Production And Operation License From Beijing Municipal Bureau Of Agriculture And Rural Affairs $INCY Eli Lilly And Incyte's Baricitinib Delivers One-Year Hair Regrowth In Adolescents With Severe Alopecia Areata; BRAVE-AA-PEDS Data To Be Presented At 2025 FCD Conference $LNT UBS Upgrades Alliant Energy to Buy, Raises Price Target to $79
0 · Reply
StockHunter75
StockHunter75 Oct. 23 at 2:40 PM
$INCY Bullish
0 · Reply
zman94
zman94 Oct. 22 at 10:40 PM
https://seekingalpha.com/article/4831678?gt=492e161a7d50b892 $INCY
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 21 at 3:29 PM
$INCY Share Price: $86.85 Contract Selected: Mar 20, 2026 $90 Calls Buy Zone: $5.95 – $7.35 Target Zone: $10.51 – $12.85 Potential Upside: 67% ROI Time to Expiration: 149 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 21 at 1:57 PM
Enter: $INCY NOV 21 2025 $88 CALLS Buy in Price: $4.00 - $4.20 Take Profit: $7.76 Stop Bleeding: $3.52 ROI Potential: 94% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
Doozio
Doozio Oct. 20 at 7:11 PM
$INCY bahhht them MNDY 🐑 🎁 s?
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 3:02 PM
Enter: $INCY NOV 21 2025 $90 CALLS Buy in Price: $3.85 - $5.50 Take Profit: $8.43 Stop Bleeding: $3.39 ROI Potential: 119% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
Varlamovnyse
Varlamovnyse Oct. 18 at 6:59 PM
$INCY strong fundamentals
0 · Reply
nikitatrades
nikitatrades Oct. 17 at 12:30 PM
Health Canada approves Incyte's $INCY Opzelura cream for treating atopic dermatitis in children aged 2+. This is the product's 3rd Canadian approval.
0 · Reply
pilobious
pilobious Oct. 17 at 3:43 AM
$INCY Incyte worth $164 on discounted cash flow basis. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/a-look-at-incytes-valuation-following-positive-early-data-fo
0 · Reply
Doozio
Doozio Oct. 16 at 11:56 PM
Da $INCY wincy spider shud not climb up da water spout on a 🐑 Thursday!
0 · Reply
OptionRunners
OptionRunners Oct. 16 at 2:27 PM
$INCY December 19th $85P/$72.50P/$100C bear seagulls opening 3,000 times for no cost ahead of earnings on 10/28
0 · Reply